Clinical Trials: Pre-Submission Meetings (FDA Type A/B/C)

Types of FDA Meetings and Their Strategic Value

Posted on digi By digi

The U.S. Food and Drug Administration (FDA) offers several types of formal meetings to help sponsors and applicants navigate the complex regulatory landscape. These meetings are not only regulatory checkpoints but also strategic tools that can streamline drug development and facilitate smoother submissions. Understanding when and how to request these meetings—especially the distinctions between Type A, Type B, and Type C—is crucial to maximizing their value.

Click to read the full article.

Pre-Submission Meetings (FDA Type A/B/C), Regulatory Submissions and Approvals

How to Draft an Effective Pre-Meeting Briefing Document

Posted on digi By digi

The briefing document is a foundational element in preparing for formal meetings with the U.S. Food and Drug Administration (FDA), including Type A, B, or C interactions. It is the first opportunity to present your development program’s context, raise critical questions, and align expectations with regulators. A well-crafted document can significantly influence the quality of feedback you receive—and ultimately the success of your regulatory submission.

Click to read the full article.

Pre-Submission Meetings (FDA Type A/B/C), Regulatory Submissions and Approvals

Timeline and Format for Requesting FDA Type B Meetings

Posted on digi By digi

Type B meetings with the FDA are the most common form of formal interaction between sponsors and the agency during drug development. These meetings occur at key milestones such as pre-Investigational New Drug (pre-IND), end-of-Phase 2 (EOP2), and pre-New Drug Application (pre-NDA) stages. They are designed to facilitate regulatory alignment before major submissions and help sponsors avoid delays or rejections due to data gaps or compliance issues.

Click to read the full article.

Pre-Submission Meetings (FDA Type A/B/C), Regulatory Submissions and Approvals

Role of Regulatory Affairs in Pre-Submission Strategy

Posted on digi By digi

In modern drug development, regulatory success is built not only on robust science but also on the strategic involvement of Regulatory Affairs (RA). The RA function is critical in planning and executing FDA pre-submission meetings, such as pre-IND, EOP2, or pre-NDA Type B meetings. Their role is to ensure regulatory expectations are understood, met, and proactively addressed long before formal submissions are filed.

Click to read the full article.

Pre-Submission Meetings (FDA Type A/B/C), Regulatory Submissions and Approvals

Comparing Type A, B, and C Meetings with Case Examples

Posted on digi By digi

Interacting with the U.S. Food and Drug Administration (FDA) is essential for successful regulatory navigation, especially in drug, biologic, or device development. The agency offers three structured meeting types — Type A, Type B, and Type C — each serving a specific purpose at different points in the product development lifecycle.

Click to read the full article.

Pre-Submission Meetings (FDA Type A/B/C), Regulatory Submissions and Approvals

Meeting Minutes: Documentation and Follow-Up Requirements

Posted on digi By digi

Meeting minutes from FDA pre-submission meetings (Type A, B, or C) serve as formal documentation of the agency’s responses and guidance. These written records are not just administrative notes—they are critical regulatory artifacts that inform a sponsor’s development decisions, future submissions, and inspection readiness. Clear, accurate, and timely documentation of FDA meeting minutes ensures that sponsors can:

Click to read the full article.

Pre-Submission Meetings (FDA Type A/B/C), Regulatory Submissions and Approvals

Dos and Don’ts in FDA Pre-Submission Interactions

Posted on digi By digi

FDA pre-submission meetings—whether Type A, B, or C—are pivotal for shaping the direction of a drug, biologic, or device development program. These sessions offer sponsors the chance to receive guidance, resolve issues, and align expectations with regulators early in the process. However, to derive value from these interactions, sponsors must understand how to conduct themselves, what to avoid, and how to present a cohesive regulatory strategy.

Click to read the full article.

Pre-Submission Meetings (FDA Type A/B/C), Regulatory Submissions and Approvals

Mock Pre-Submission Meetings: Are They Worth It?

Posted on digi By digi

A mock pre-submission meeting is a simulated regulatory interaction where a sponsor team rehearses the format, flow, and content of an actual FDA meeting (Type A, B, or C). These rehearsals are typically conducted before engaging with the FDA to build internal alignment, test messaging, and identify gaps in preparation. While not mandated by regulatory authorities, mock meetings have become a best practice among top-tier pharmaceutical, biotech, and medical device companies.

Click to read the full article.

Pre-Submission Meetings (FDA Type A/B/C), Regulatory Submissions and Approvals

Use of Pre-Submission Pathways for Device Approvals

Posted on digi By digi

The FDA’s Pre-Submission program, often referred to as the Q-Submission or “Q-Sub” process, is a formal pathway that allows medical device sponsors to request feedback from the Center for Devices and Radiological Health (CDRH) or Center for Biologics Evaluation and Research (CBER) before submitting regulatory applications such as:

Click to read the full article.

Pre-Submission Meetings (FDA Type A/B/C), Regulatory Submissions and Approvals

FDA Meeting Management Systems and e-Tools

Posted on digi By digi

Pre-submission meetings—whether Type A, B, or C—require precise coordination, documentation, and compliance with regulatory timelines. As the volume and complexity of submissions grow, the U.S. FDA has increasingly adopted electronic systems and tools to streamline interactions with sponsors. These e-tools enable faster meeting scheduling, better document handling, and improved transparency for both regulators and sponsors.

Click to read the full article.

Pre-Submission Meetings (FDA Type A/B/C), Regulatory Submissions and Approvals